- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ginkgo Bioworks Holdings (DNA)
Ginkgo Bioworks Holdings stock price live, this page displays NYSE DNA stock exchange data. View the DNA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Ginkgo Bioworks Holdings real time stock price chart below.
What Is the Ginkgo Bioworks Holdings Stock Price Today?
The Ginkgo Bioworks Holdings stock price today is 13.380.
What Is the Stock Symbol for Ginkgo Bioworks Holdings?
The stock symbol for Ginkgo Bioworks Holdings is ""DNA.""
What Stock Exchange Does Ginkgo Bioworks Holdings Trade On?
Ginkgo Bioworks Holdings is listed and trades on the NYSE stock exchange.
Is Ginkgo Bioworks Holdings a Good Stock to Buy?
Determining whether Ginkgo Bioworks Holdings—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DNA quote. (ISIN: US37611X2099)
What Is the Ginkgo Bioworks Holdings Stock Price Today?
The Ginkgo Bioworks Holdings stock price today is 13.380.
What Is the Stock Symbol for Ginkgo Bioworks Holdings?
The stock symbol for Ginkgo Bioworks Holdings is ""DNA.""
What Stock Exchange Does Ginkgo Bioworks Holdings Trade On?
Ginkgo Bioworks Holdings is listed and trades on the NYSE stock exchange.
Is Ginkgo Bioworks Holdings a Good Stock to Buy?
Determining whether Ginkgo Bioworks Holdings—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DNA quote. (ISIN: US37611X2099)
13.380
-0.580(-4.15%)
Real-time Data·
Fair Value
An estimate of a Ginkgo Bioworks's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.280
13.814
52 wk Range
5.000
16.850
DNA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
DNA is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a Ginkgo Bioworks's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.28013.814
52 wk Range
5.00016.850
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DNA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Ginkgo Bioworks's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Neutral
Price Target
8.667
Downside
-35.23%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Ginkgo Bioworks appoints Steven Coen as CFO
- Investing.com
- Ginkgo Bioworks appoints Steven Coen as new CFO
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Ginkgo Bioworks Holdings Company Profile
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company serves the pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Ginkgo Bioworks Holdings Earnings Call Summary for Q1/2025
- Q1 2025 cell engineering revenue up 37% YoY to $38M; total adjusted EBITDA improved to -$47M from -$117M in Q1 2024
- Stock fell 6.79% to $6.92 post-earnings, recovered slightly in aftermarket; company aims for adjusted EBITDA breakeven by end of 2026
- Full-year revenue guidance set at $167M-$187M; focus on expanding tools business, automation offerings, and biosecurity opportunities
- Cash burn reduced to $58M from $104M in Q1 2024; $517M cash on hand with no bank debt; Altman Z-Score at concerning -6.5
- CEO emphasizes company's resilience amid biotech sector challenges; new product launches and government contracts to drive growth
Last Updated: 06/05/2025, 23:50
Read Full TranscriptCompare DNA to Peers and Sector
Metrics to compare | DNA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDNAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.7x | −5.8x | 2.5x | |
PEG Ratio | −0.03 | 0.00 | 0.00 | |
Price/Book | 1.2x | 1.4x | 1.6x | |
Price / LTM Sales | 3.4x | 3.7x | 1.3x | |
Upside (Analyst Target) | −41.6% | 12.1% | 19.2% | |
Fair Value Upside | Unlock | −7.7% | 1.9% | Unlock |
Analyst Ratings
1 Buy
0 Hold
3 Sell
Ratings:
4 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 8.667
(-35.23% Downside)
Earnings
Latest Release
May 06, 2025
EPS / Forecast
-1.68 / -0.06
Revenue / Forecast
48.32M / 47.45M
People Also Watch
FAQ
What Stock Exchange Does Ginkgo Bioworks Trade On?
Ginkgo Bioworks is listed and trades on the New York Stock Exchange stock exchange.
What Is the Stock Symbol for Ginkgo Bioworks?
The stock symbol for Ginkgo Bioworks is "DNA."
What Is the Ginkgo Bioworks Market Cap?
As of today, Ginkgo Bioworks market cap is 785.79M.
What Is Ginkgo Bioworks's Earnings Per Share (TTM)?
The Ginkgo Bioworks EPS (TTM) is -8.92.
From a Technical Analysis Perspective, Is DNA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Ginkgo Bioworks Stock Split?
Ginkgo Bioworks has split 1 times.
How Many Employees Does Ginkgo Bioworks Have?
Ginkgo Bioworks has 834 employees.
What is the current trading status of Ginkgo Bioworks (DNA)?
As of 29 Jul 2025, Ginkgo Bioworks (DNA) is trading at a price of 13.38, with a previous close of 13.96. The stock has fluctuated within a day range of 13.28 to 13.81, while its 52-week range spans from 5.00 to 16.85.
What Is Ginkgo Bioworks (DNA) Price Target According to Analysts?
The average 12-month price target for Ginkgo Bioworks is USD8.66667, with a high estimate of USD12 and a low estimate of USD6. 1 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Neutral. The stock has an -35.23% Downside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.